The Israeli company Accelerated Evolution Biotechnologies claim to be working on a cure for cancer that uses phage display technology — which won scientists the Nobel Prize last year.
A team of scientists at Israeli company Accelerated Evolution Biotechnologies Ltd. (AEBi) believe to have developed an all-encompassing cure for cancer that’s set to be ready for testing in one year’s time.
Company owner Dan Aridor is confident that AEBi’s approach will not only successfully treat cancer patients and give them a new lease on life, but that the medicine in development — currently dubbed MuTaTo, or multi-target toxin — will be extremely cost-effective and pose little to no danger.
“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” he said. “Our solution will be both generic and personal.”
The International Agency for Research on Cancer estimates new cancer diagnoses at about 18.1 million cases per year. The prevalence of the disease is universally relatable, as many of us have friends, relatives, or acquaintances who’ve endured it. While a cure for cancer is seemingly always purported to be around the next corner, MuTaTo — and its properties, as described — sound fairly promising.
Morad explained that most anti-cancer drugs merely attack a specific target and don’t account for the pathways that target uses to mutate or reproduce. MuTaTo was developed to combine numerous cancer-killing peptides for each individual cell simultaneously, in addition to a strong toxin that attacked malignant cells.
“We used to give AIDS patients several drugs, but we would administer them one at a time,” he said. “During the course of treatment, the virus mutated, and the AIDS started attacking again. Only when patients started using a cocktail, were they able to stop the disease.”
“Instead of attacking receptors one at a time, we attack receptors three at a time — not even cancer can mutate three receptors at the same time,” he said.
As it stands, AEBi is writing patents on particular peptides it’s found most effective in order to curate a database of treatments it can own. Dr. Morad said the first experiment on mice, as well as numerous in-vitro trials, have been successful.
“Our results are consistent and repeatable,” said Aridor. His company is now gearing up for clinical trials, which will take years to complete. If he’s correct, this could be one of the most significant scientific efforts in human history. We’ll just have to wait and see.